Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Serum amyloid P-component

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Roche

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

1

Protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

DRUG BANK

2

FDA ORPHAN DRUG

2

FDA UNII

2

INN

2

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated/Withdrawn|Treatment of AL amyloidosis" in comments (approximate match)

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Miridesap

WO97N24A47

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Serum amyloid P-component

RO-638695 (also known as Miridesap, CPHPC and GSK-2315698) is an antineoplastic and a serum amyloid P component inhibitor. RO-638695 almost completely depletes circulating serum amyloid P component (SAP), but a small amount of SAP is left for recogni...

tion by subsequently administered therapeutic IgG anti-SAP antibodies. SAP is a blood protein that is the target of a novel immunotherapy approach. RO-638695 has therefore been evaluated in phase I and II clinical trials for its safety and potential in treatment of diseases like Alzheimer’s disease, HIV infection and other diseases with systemic amyloid deposition.

DEZAMIZUMAB

6U3F28IT58

Subunit 1 (452) Similarity Search Subunit 2 (452) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (452) Similarity Search Subunit 2 (452) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

Investigational

Class:

PROTEIN

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1